As of April 13, 2020, A novel coronavirus, also known as COVID-19 or SARS-CoV-2 has been confirmed in 1,858,800 people worldwide, carrying a mortality of approximately 3.4%. As COVID-19 cases increase day by day, scientists are digging to reveal all about this pandemic virus, and many drug suggestions have been under clinical trials to decrease the mortality based on the theory of " cytokine storm- hyperinflammatory status". However new researches and studies have discovered that the reactive oxygen species (ROS) storm instead of cytokine storm is the primary pathogenesis cascade that contributes to the exponential mortality pattern in in late stage COVID-19 infected critically ill patients. The impact of COVID-19 on the health, economic and political systems made it a hot topic for research. Therefore, new drug ideas that deals with the underlining contributors of the disease are needed. In this review article, we aim to introduce a novel management strategy using continuous Desferrioxamine (an iron chelating agent) infusion with adjunctive PRBCs based on the new theory of the disease pathogenesis named as "Iron overload-hyperoxidative status-radical storm" and the extrapolation of the clinical outcomes of this strategy in blood transfusion dependent thalassemia.